- Home
- GLPG vs WAFD Comparison
GLPG vs WAFD Comparison
Compare GLPG & WAFD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLPG | WAFD |
|---|---|---|
| Founded | 1999 | 1917 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | GLPG | WAFD |
|---|---|---|
| Price | $33.18 | $32.97 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 5 |
| Target Price | $31.33 | ★ $31.40 |
| AVG Volume (30 Days) | 101.5K | ★ 551.4K |
| Earning Date | 02-11-2026 | 01-15-2026 |
| Dividend Yield | N/A | ★ 3.28% |
| EPS Growth | N/A | ★ 5.31 |
| EPS | N/A | ★ 2.63 |
| Revenue | $336,643,201.00 | ★ $717,732,000.00 |
| Revenue This Year | $1.76 | $8.66 |
| Revenue Next Year | $0.49 | $4.77 |
| P/E Ratio | ★ N/A | $12.54 |
| Revenue Growth | ★ 10.31 | 1.95 |
| 52 Week Low | $22.36 | $23.75 |
| 52 Week High | $37.78 | $33.92 |
Technical Indicators
Market Signals| Indicator | GLPG | WAFD |
|---|---|---|
| Relative Strength Index (RSI) | 60.18 | 54.41 |
| Support Level | $32.33 | $31.52 |
| Resistance Level | $33.91 | $33.25 |
| Average True Range (ATR) | 0.67 | 0.65 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 67.51 | 60.08 |
Price Performance
Historical ComparisonAbout GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About WAFD WaFd Inc.
WaFd Inc is engaged in providing lending, depository, insurance, and other banking services to consumers, mid-sized to large businesses, and owners and developers of commercial real estate. Through the WaFd Bank, it is involved in accepting deposits from the general public and investing these funds in loans of various types, including first-lien mortgages on single-family dwellings, construction loans, land acquisition and development loans among others. The Bank also invests in certain United States government and agency obligations along with other investments and also performs insurance brokerage activities. Geographically, it operates in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico, California and Texas.